Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'.
about
Pharmacological treatments for acute hepatitis B infection: a network meta-analysisUrsodeoxycholic acid for primary biliary cirrhosisBile acids for non-alcoholic fatty liver disease and/or steatohepatitisBile acids: regulation of apoptosis by ursodeoxycholic acidA Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLDChanges in hepatic gene expression upon oral administration of taurine-conjugated ursodeoxycholic acid in ob/ob miceProgressive familial intrahepatic cholestasis.Clinical application of transcriptional activators of bile salt transporters.Constituents of bile, bilirubin and TUDCA, protect against oxidative stress-induced retinal degenerationHepatocellular carcinoma prevention: a worldwide emergence between the opulence of developed countries and the economic constraints of developing nations.Ursodeoxycholic acid treatment of vanishing bile duct syndromes.Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression.Hepatocyte death: a clear and present danger.Primary sclerosing cholangitis: updates in diagnosis and therapyInvestigational pharmacologic treatment for liver disease.Hydrophilic bile acids protect human blood-brain barrier endothelial cells from disruption by unconjugated bilirubin: an in vitro studySystematic review: ursodeoxycholic acid--adverse effects and drug interactions.Oral solubilized ursodeoxycholic acid therapy in amyotrophic lateral sclerosis: a randomized cross-over trialThe diagnosis and treatment of primary biliary cirrhosisApproach to a patient with elevated serum alkaline phosphatase.The evolving landscape of neurotoxicity by unconjugated bilirubin: role of glial cells and inflammation.Review article: current management of primary sclerosing cholangitis.Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode.Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cellsDrug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis.Bile acid interactions with cholangiocytes.Primary biliary cirrhosis and Sjögren's syndrome: autoimmune epithelitis.The unfinished business of primary biliary cirrhosisUrsodeoxycholic acid decreases age-related adiposity and inflammation in miceHigh-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis.Intestinal bile acid physiology and pathophysiology.KASL clinical practice guidelines: management of nonalcoholic fatty liver disease.Clinical usefulness of ursodeoxycholic acid for Japanese patients with autoimmune hepatitis.Pharmacological treatment of biliary cirrhosis with ursodeoxycholic acid.Autoimmune hepatitis in children: diagnosis, pathology and treatment.Treatment options for primary sclerosing cholangitis.Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications.Canalicular ABC transporters and liver disease.Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets.ALSUntangled no. 25: ursodiol.
P2860
Q24186837-1A864363-6B43-4E76-9D06-193CF39EF5DBQ24202184-8E0ECE48-354D-49B8-99F4-4C8065B6B185Q24243149-592BD07C-4D18-468F-9547-BF69F7FF86A6Q24653969-695C0153-0AC3-40F5-B700-089BA8FDFBB7Q26752487-D2FAE9C5-DD13-47A6-B9B0-E7A3C904F3CEQ28476015-384DDD11-DA6C-4B89-AEA4-D249F5C2F86EQ33595403-26A1AD7C-1C4D-4906-AFBB-B8391D596E19Q33709930-D27AFE82-C6C3-4320-98D8-222B7B5BB27CQ33853136-A5FF9C53-2D69-4416-8967-FB43A4DE59AFQ33866448-E4F9C346-9CED-49AB-BCE2-C0AEF37ECD81Q33866782-C3A1238B-D9F9-413C-8112-835D1A2A5572Q34083354-20C6E4FF-12DA-4FA0-ABEE-5A9AB7B035CBQ34147508-EF44567D-E759-4C2A-AA2B-8B8FFA058C28Q34382536-86C18177-9CE9-47CD-80C1-03B347D942F9Q34841865-720E8638-93A4-4884-A6E2-16DCBA811CB2Q35172521-DA247FE2-C61D-4579-BE84-C9C37114ECE7Q35583064-811396E3-44DB-41FF-83AF-0C6114426F7FQ35730907-5B06905F-D060-449E-BE4A-F4BD0B32BA97Q35833175-94AB06FD-BD57-4CF4-8B26-F42980654809Q35926418-8F0406A2-10CE-4DB5-B175-A4806096148CQ35992575-2FA5B5A5-5A6D-4F0A-91C5-9A9487775FEDQ36090744-12A47DC3-2789-4FDE-B8D3-1578840A5CBDQ36197335-5234AE36-E155-42B6-BDB5-4EAED0BFF88EQ36330872-3F23709D-4625-4C54-9ACF-55CF932F5357Q36495172-F33D278A-1821-489E-A3B0-03ADFF136410Q36506491-590F192A-628C-462B-92CB-FE25A7D0EE4FQ36599248-41A53ABB-658F-4A22-8499-EE70598FB369Q36914332-8267118F-9D76-4645-8FEF-DEB5817E3B08Q37024454-F4117FED-00FE-43A6-9E18-1F642F86CFCDQ37117971-8A2F7CE3-1DD3-4A0C-9F44-A40310CD6E2DQ37287597-8ACAF921-D0C6-440E-BAB8-763B8C55E4D6Q37488800-93B49788-6C2E-4F81-8677-DFAA61EC08CCQ37570952-00BEDBD1-E952-45C6-8DAD-E76258355440Q37681567-6F73B398-564A-4249-9238-E540450064D0Q37754771-7D0BBAD7-05D4-45E6-A6CF-80FFCCDE49E4Q37777156-D416C193-6953-41A4-8F6A-3D8819A82B34Q37919924-6BF12804-9C7B-4E95-92BE-C2FDD5A86857Q37943784-1B992342-F480-4AD6-A798-FC3445F4E22BQ38160948-A4C51649-D625-45DE-934C-B92C973C2F6CQ38223869-C5F611A8-1591-4772-8E7C-938A9B116995
P2860
Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
name
Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'.
@ast
Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'.
@en
Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'.
@nl
type
label
Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'.
@ast
Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'.
@en
Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'.
@nl
prefLabel
Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'.
@ast
Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'.
@en
Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'.
@nl
P2093
P1476
Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'.
@en
P2093
K D Lindor
K N Lazaridis
P304
P356
10.1016/S0168-8278(01)00092-7
P577
2001-07-01T00:00:00Z